Dr. Levy is currently CEO of Ocunexus Therapeutics a clinical stage company developing ophthalmic products. Ocunexus compounds target Connexin43 Hemichannels inhibiting activation of the inflammasome in GA and DR, with an oral drug.
Prior to OcuNexus he was Chief Medical Officer at Aerie Pharmaceuticals developing Rho Kinase Inhibitors for lowering IOP, Rhopressa recently approved.
He was Corporate Vice President and Chief Medical Officer, Bausch & Lomb, responsible for 3 NDA’s, 4 PMA’s and multiple 510K’s all FDA approved, including Retisert the first drug delivery system to deliver a steroid intravitreally.
He was Associate Professor, Ophthalmology, California Pacific Medical Center and prior to that practiced in Toronto and was a consultant to the ophthalmic industry. Dr. Levy sits on 3 boards of companies developing ophthalmic products.